The AADAPT Act reauthorizes and expands Project ECHO grants to improve Alzheimer’s and dementia care through technology-enabled training. It specifically funds grants for healthcare providers in rural, frontier, or medically underserved areas to enhance early diagnosis, quality care, and provider retention for dementia patients. The bill authorizes $1 million annually (2027-2032) for these dementia-focused training programs, requiring funds to supplement - not replace - existing resources. This directly supports primary care providers licensed to serve underserved communities, using collaborative online learning to address care gaps.
HR 2821, the FDA Modernization Act 3.0, requires the FDA to update regulatory language within one year of enactment. It directs the agency to replace all references to "animal tests" with "nonclinical tests" in 22 specific sections of the Code of Federal Regulations related to drug development and approval processes. The bill also adds a definition for "nonclinical test" into relevant FDA regulations to align with prior legislative changes. This update applies directly to pharmaceutical manufacturers and FDA reviewers who follow these regulatory guidelines during drug development. The changes aim to modernize terminology without altering current testing requirements.
HR 2004, titled "Tyler’s Law," requires the Secretary of Health and Human Services to study how often hospital emergency departments test for fentanyl during overdose cases (beyond standard drug tests), including associated costs, patient benefits/risks, and impacts on privacy and patient-physician relationships. The study must be completed within one year of the bill's enactment. Based on the study results, the Secretary must issue guidance within six months on whether emergency departments should routinely test for fentanyl, how to inform clinicians about test contents, and how such testing may affect future overdose risks and health outcomes. This bill directly affects hospital emergency departments and patients experiencing overdoses by shaping future testing protocols.
HR 1266, the Combating Illicit Xylazine Act, adds xylazine - a veterinary sedative increasingly found in illicit drug mixtures - to Schedule III of the Controlled Substances Act, regulating its use and trafficking. It directly affects veterinarians, animal owners, and manufacturers by allowing xylazine to be legally dispensed for animal use under specific veterinary prescriptions, while prohibiting non-veterinary human use. The bill includes transition periods (60 days for practitioners, 1 year for labeling) to ease compliance for manufacturers and practitioners, and requires the DEA and FDA to expedite necessary applications. It also mandates two congressional reports on xylazine's illicit use and trafficking patterns, and directs the Sentencing Commission to review penalties for offenses involving xylazine.
This bill creates a new program to speed up the approval process for specific over-the-counter drugs that could offer significant public health benefits. Drug companies can request this "priority" status for new medications intended for conditions that currently require a prescription, provided the drugs are new or contain active ingredients never seen in nonprescription products. If approved, the FDA will assign senior staff and specialized teams to work closely with the companies, offering faster guidance and more efficient review schedules while maintaining the same safety and effectiveness standards. The program includes a requirement to publish a list of eligible health conditions and will expire in September 2032 unless renewed by Congress.
HR 2913, the Ukraine Support Act, provides comprehensive U.S. support for Ukraine in response to Russia's invasion. The bill authorizes security assistance including lend-lease authority for military equipment, establishes a Ukraine Reconstruction Trust Fund for economic recovery, and imposes new sanctions targeting Russian financial institutions, oil companies, and government officials. It also includes provisions to counter Russian disinformation, support Radio Free Europe, and address the kidnapping of Ukrainian children. The legislation directly affects U.S. foreign policy, Ukraine's defense capabilities, and Russia's access to international financial systems. The act aims to strengthen Ukraine's sovereignty while holding Russia accountable for its actions.
This bill establishes a legal framework allowing banks and credit unions to provide financial services to businesses operating marijuana or hemp industries under state laws without fear of losing federal protections. It specifically shields these institutions from penalties, insurance termination, or liability if they accept deposits or make loans to state-sanctioned marijuana or hemp companies. The legislation also clarifies that income from these businesses can be used to qualify for federally backed mortgages and requires regulators to update guidance on how to handle suspicious activity reports related to these sectors. Additionally, the bill mandates annual reports and studies to assess access to banking services for minority-owned and small businesses within the industry.
This resolution honors the life and legacy of the late Senator Lindsey Olin Graham from South Carolina. It formally acknowledges his extensive career in the military, state government, and Congress, noting his service as a Senator and his roles as Chairman of the Judiciary and Budget committees. The Senate expresses its sorrow over his death and requests that this tribute be shared with the House of Representatives and Graham's family.
The Ratepayer Protection Act establishes a new federal standard to protect utility customers from high electricity bills caused by large industrial users. It defines "large-load customers" as non-residential entities with a peak power demand of 100 megawatts or more that primarily use electricity for data centers and computing. Under this bill, these customers must pay for the full cost of any power plant, transmission line, or distribution upgrade needed to serve them, including costs incurred if the customer leaves the utility early. Additionally, utilities are required to obtain financial guarantees from these large customers before making such infrastructure investments. State regulators must review and implement these rules within two years, unless a state has already enacted similar protections.
This bill establishes a comprehensive sanctions framework targeting the Russian government and its affiliated entities in response to ongoing military actions. It authorizes the President to block assets, revoke visas, and prohibit financial transactions for Russian officials, military leaders, and foreign persons supporting Russia's defense industry or undermining Ukraine. The legislation also bans U.S. investments in Russian energy sectors, prohibits the purchase of Russian sovereign debt, and imposes high tariffs on Russian imports while restricting crude oil purchases by specific foreign nations. Additionally, the bill prevents Russian companies from listing on U.S. stock exchanges and includes mechanisms for terminating sanctions only if Russia signs a peace agreement accepted by Ukraine and ceases hostilities.
The NO BOSS Act modifies federal rules to allow individuals receiving unemployment benefits to start self-employment businesses without first exhausting their regular benefits. It requires that these self-employment activities include approved entrepreneurial training, business counseling, or a submitted business plan with a market feasibility study. The changes take effect two years after enactment, though states are permitted to adopt similar rules earlier. The Department of Labor will issue regulations and guidance to help state agencies implement these new requirements.
The Fertility Cost Relief Act allows individuals to withdraw up to $20,000 from their retirement accounts to pay for fertility treatments without incurring the usual early withdrawal penalty. This provision directly affects people seeking assisted reproductive technologies, such as in vitro fertilization, egg or sperm preservation, and fertility medications, as well as their spouses or domestic partners. The bill defines eligible expenses broadly and sets a lifetime limit on penalty-free withdrawals, with the dollar amount adjusted for inflation after 2026. To use this benefit, the funds must be spent on qualifying treatments within one year of being withdrawn from an eligible retirement plan.
